Clinical trials: 2019-nCoV
COVID-19 Infection
Clinical Characteristics and Prognostic Factors of Patients With COVID-19 (Coronavirus Disease 2019)
This is a multicenter, non-interventional, retrospective study using data captured in the EHRs (Electronic Health Records) of the participating hospital sites to determine factors that predict disease prognosis and outcomes in…
- Trial name
- NCT04569851
- Where
- 2 sites in Spain
- Volunteers
- 100,000 people
- Sponsor
- Savana Research
COVID-19
Rehabilitation in Severely Ill Inpatients With COVID-19
Inpatient rehabilitation of severe-to-critical COVID-19 patients(A longitudinal, single-center retrospective cohort)
- Trial name
- NCT05104411
- Testing
- Rehabilitative intervention
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Seoul National University Bundang Hospital
Acute Disease, Coronavirus
Evaluation of Novel Diagnostic Tests for COVID-19
COVID-19 (also known as Coronavirus) originated in the Wuhan China and has since spread to at least 159 countries around the world. It was declared a pandemic by the World health organisation on the 11th of March 2020.
- Conditions
- Acute Disease, Coronavirus, Respiratory Viral Infection
- Trial name
- COVIDx (NCT04326387)
- Testing
- SAMBA II (Diagnostic for the Real World), Public Health England Gold Standard, Cambridge Validated Viral Detection Method
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- CCTU- Cancer Theme
Coronavirus Infections
French COVID Cohort
Infectious disease is the single biggest cause of death worldwide. New infectious agents, such as the SARS, MERS and other novel coronavirus, novel influenza viruses, viruses causing viral haemorrhagic fever (e.g.
- Trial name
- FrenchCOVID (NCT04262921)
- Where
- 98 sites in France
- Volunteers
- 4,415 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Virus; Pneumonia
A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia
Due to the outbreak of 2019 Novel Coronavirus Pneumonia in Wuhan, Hubei province, medical staff and residents are facing great psychological pressure, the investigator plan to use electronic questionnaire to carry out…
- Trial name
- NCT04260308
- Where
- China
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- Huazhong University of Science and Technology
COVID-19, SARS-CoV-2
Monitoring Serologic Response to Severe Acute Respiratory Syndrome-2 (SARS-COV-2)/COVID-19 in Children
Individuals susceptible to SARS-CoV-2 and the illness it causes (COVID-19) are comprised of heterogeneous populations with a large risk spectrum for more severe disease.
- Conditions
- COVID-19, SARS-CoV-2, Inflammatory Bowel Diseases
- Trial name
- RECONN (NCT04838834)
- Where
- United States
- Volunteers
- 472 people
- Sponsor
- Connecticut Children's Medical Center
Covid19
Detection of COVID-19 Using Breath Analysis - Validation Study
DETECTION OF THE 2019 NOVEL CORONAVIRUS (SARS-CoV-2) USING BREATH ANALYSIS- VALIDATION STUDY
- Trial name
- COVID-19 (NCT04602949)
- Testing
- Breath Biopsy Analysis
- Where
- Israel
- Volunteers
- 2,558 people, healthy volunteers welcome
- Sponsor
- Scentech Medical Technologies Ltd
COVID-19
COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age
The primary objective of the study is to characterize the concentrations of casirivimab+imdevimab in serum over time after a single subcutaneous (SC) administration The secondary objectives of the study are: To assess the safety…
- Trial name
- NCT04992273
- Testing
- casirivimab+imdevimab
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Regeneron Pharmaceuticals
Coronavirus
Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection
Outbreak of 2019 Novel Coronavirus infection started in Wuhan and quickly spread to the world. Suspected patients were isolated and treated in our department.
- Trial name
- NCT04279782
- Testing
- Comprehensive treatment
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Covid19
Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
The COMET-TAIL main study evaluated efficacy, safety, and tolerability of IM sotrovimab versus IV sotrovimab in high-risk patients for the treatment of mild/moderate COVID-19.
- Trial name
- NCT04913675
- Testing
- sotrovimab
- Where
- 50 sites in United States, France and 1 more
- Volunteers
- 1,065 people
- Sponsor
- Vir Biotechnology, Inc.
New Coronavirus
Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV
In late December 2019, several local health facilities reported clusters of patients with pneumonia of unknown cause that were epidemiologically linked to a seafood and wet animal wholesale market in Wuhan, Hubei Province, China.
- Trial name
- NCT04245631
- Testing
- Recombinase aided amplification (RAA) assay
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing Ditan Hospital
COVID-19
Specimen Collection Study From Coronavirus Disease 2019 (COVID-19) Vaccinated Adults and Adolescents
This is a specimen collection study intended to generate a biological specimen repository of samples from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naïve adults and adolescents ≥12 years old who will receive…
- Trial name
- CoVacSpec (NCT05252910)
- Where
- 32 sites in United States, Colombia and 5 more
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Pharm-Olam, LLC
Acute Pancreatitis, 2019 Novel Coronavirus Infection
Study and Analysis of Acute Pancreatitis Complicated With COVID-19
The goal of this observational study was to explore the complex relationship between changes in the intestinal microbiome and serum metabolites in patients with novel coronavirus infection and acute pancreatitis.
- Trial name
- NCT05722678
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Yuansong Sun
COVID-19 (Coronavirus Disease 2019)
Physiological Finding in Management of COVID 19 Patients
This study utilizes physiological indicators of COVID-19 patients as tools for assessing, tracking, worsening, and improving the clinical symptoms of COVID-19 patients.
- Trial name
- COVID-19 (NCT07504341)
- Testing
- physiological parameters
- Where
- 2 sites in Taiwan
- Volunteers
- 15,000 people
- Sponsor
- St. Martin De Porress Hospital
Covid19
Risk Factors Worsening COVID19 for Out-patient With Home Monitoring
The main objective of the COVIDADOMEVA study is to identify the risk factors aggravating the COVID-19 (risk or protective factors), in out-patients suspected of being infected with precocious home monitoring.
- Trial name
- COVIDADOMEVA (NCT04380662)
- Testing
- Risk factors
- Where
- France
- Volunteers
- 800 people
- Sponsor
- University Hospital, Grenoble
Coronavirus Infections, Severe Acute Respiratory Syndrome
Household Transmission Investigation Study for COVID-19 in Tropical Regions
This study is a interventional study that present minimal risks and constraints to evaluate the presence of novel coronavirus (SARS-CoV-2) or antibodies among individuals living in households where there is a confirmed…
- Conditions
- Coronavirus Infections, Severe Acute Respiratory Syndrome, SARS-CoV Infection
- Trial name
- EPI-COVID-19 (NCT04328129)
- Testing
- Human biological samples
- Where
- 4 sites in French Guiana, Guadeloupe and 1 more
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
SARS Coronavirus (SARS-CoV-2) Infection
A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19
This study is to gain critical knowledge to understand the factors influencing the outcome of a pandemic virus within the city of Basel.
- Trial name
- NCT04351503
- Testing
- Study A, Study B, Study C
- Where
- 6 sites in Switzerland
- Volunteers
- 126,586 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Coronavirus Disease 2019
Expanded Access Remdesivir (RDV; GS-5734™)
Disease caused by 2019 Novel Coronavirus also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Trial name
- NCT04302766
- Testing
- Remdesivir
- Where
- 22 sites in United States, Afghanistan and 6 more
- Sponsor
- U.S. Army Medical Research and Development Command
Covid19, SARS (Severe Acute Respiratory Syndrome)
Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Coronavirus Disease 2019 (COVID-19) (previously called 2019-nCOV acute respiratory disease) is caused by SARS-CoV-2, a positive-sense single-stranded RNA virus of the coronavirus family.
- Trial name
- NCT04590274
- Testing
- Hydroxychloroquine, Vitamins and Minerals, Azithromycin
- Volunteers
- healthy volunteers welcome
- Sponsor
- International Brain Research Foundation
Coronavirus Disease 2019 (COVID-19), SARS-CoV-2
COVID-19: Human Epidemiology and Response to SARS-CoV-2
The human disease caused by SARS-CoV-2 is called COVID-19. In most cases, COVID-19 presents as a mild to moderate respiratory illness. But it can also be more severe and even lead to death.
- Trial name
- HEROS (NCT04375761)
- Testing
- Collection of Biological Samples, Symptom and Exposure Surveys
- Where
- 20 sites in United States
- Volunteers
- 5,599 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)